Tirzepatide

Tirzepatide is a synthetic dual-incretin agonist peptide engineered to activate GLP-1R and GIPR, two core class B G protein-coupled receptors within the gastrointestinal metabolic signaling network. This dual-receptor mechanism regulates pancreatic insulin secretion, hepatic glucagon production, gastric emptying and central hypothalamic appetite signaling, making it a core research tool for obesity, type 2 diabetes and metabolic syndrome preclinical studies.

Researchers globally can source Tirzepatide 10 mg lyophilized powder from Zypep Peptides Co., Limited (zypep.com). All batches undergo independent third-party HPLC identity and purity testing, with full Certificates of Analysis (COA) supplied for traceability, laboratory audit and academic research documentation. Every vial meets strict endotoxin limits for cell and animal model experiments.

Tirzepatide Structure and Design

Tirzepatide is built on a native human GIP peptide backbone with targeted amino acid substitutions and lipid conjugation to optimize receptor affinity and metabolic stability:

Compared to single-target GLP-1 analogs, tirzepatide’s dual GIP/GLP-1 activation amplifies satiety signaling and improves glycemic regulation, supporting research into synergistic multi-hormone metabolic pathways.

Chemical properties and registry information

Clinical data and research background

Tirzepatide is one of the most widely studied incretin research peptides, supported by large-scale Phase 2 and Phase 3 clinical trial datasets published in top metabolic journals. Core published research programs include the SURMOUNT clinical series, which documented dose-dependent body weight reduction and HbA1c lowering across overweight, obese and diabetic subject cohorts.

For laboratory investigators, these published datasets provide critical baseline reference data for designing comparative metabolic studies against semaglutide, retatrutide and other incretin mimetics. All trial summaries referenced on our website are for scientific literature reference only; Zypep Peptides products are strictly lyophilized research raw materials and not for human therapeutic administration.

SURMOUNT-1 landmark Phase 3 trial (Jastreboff et al., NEJM 2022)

The SURMOUNT-1 randomized, double-blind, placebo-controlled trial evaluated weekly tirzepatide doses over 72 weeks in participants with BMI ≥30 kg/m². At the maximum tested dose, mean body weight reduction reached 22.5% from baseline, establishing the peptide’s robust dual-receptor metabolic activity and forming the foundational reference for modern obesity peptide research.

Wholesale supply support

Zypep Peptides supplies bulk wholesale tirzepatide powder to research labs, cosmetic R&D institutions and preclinical CROs worldwide. Contact our online inquiry dialog on zypep.com to request batch COA, bulk pricing and global shipping terms. All products marked FOR RESEARCH USE ONLY.